• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Updates to Polymyalgia Rheumatica Care: Sarilumab Insights


Dana McCormick, R.Ph., and Robert Spiera, M.D., delve into the SAPHYR trial, discussing sarilumab’s role in managing polymyalgia rheumatica relapse during glucocorticoid tapers.

This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.

Robert Spiera, M.D., highlights the initial success of steroid therapy, yet the prolonged use poses significant challenges due to side effects. Patients, especially older individuals with comorbidities, face increased vulnerability to steroid-related toxicity, with up to 65% experiencing notable side effects. Managing polymyalgia rheumatica evolves from the initial relief to the long-term impact of steroid-related complications.

He emphasizes the dilemma: Extended steroid use addresses polymyalgia rheumatica symptoms but exacerbates health risks. Without an alternative to control disease activity, patients face functional limitations. The discussion underscores the critical need for new therapies like sarilumab to address polymyalgia rheumatica relapse during glucocorticoid tapers, offering hope for improved disease management while mitigating steroid-related challenges in long-term treatment.

This summary was AI-generated and reviewed by Managed Healthcare Executive® staff.

Related Videos
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Video 2 - "Holistic Fertility Management and Payer Collaboration"
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Related Content
© 2024 MJH Life Sciences

All rights reserved.